Quick answer: No. HHS did not approve any peptides. In late October 2026, HHS said it does not plan to take action against licensed pharmacies that make six peptides, including BPC-157, for individual patients who have a prescription, as long as strict rules are followed. That is not FDA approval, and it does not mean these peptides are proven safe or effective. The policy is temporary and not binding, and human research is still very limited.
Medically reviewed by Dr. Hootan Zandifar, MD, Medical Director, Regen Therapy MD (UCLA David Geffen School of Medicine). Educational information only — not medical advice; individual results vary.
What happened?
In late October 2026, the U.S. Department of Health and Human Services (HHS) announced a new policy on peptides. HHS published a notice about the policy in the Federal Register on October 30, 2026. It came from the HHS Secretary's office, not from the FDA.
The policy covers compounding. Compounding is when a pharmacy mixes a medication for one specific patient. HHS said it does not plan to take action against licensed pharmacies and physicians that compound six peptides for individual patients, as long as they follow strict rules.
The six peptides are:
- BPC-157
- TB-500
- Epitalon (also spelled epithalon)
- Semax
- KPV
- MOTS-c
The policy names only these six. It does not cover other peptides.
Does this mean these peptides are approved or proven safe?
No. This is the most important point.
The legal term for this policy is "enforcement discretion." In plain words, HHS is saying it does not plan to penalize pharmacies for this, under certain rules. It is not saying these peptides are approved or proven.
Here is what the policy does not do, based on the HHS documents as of November 6, 2026:
- It is not FDA approval. None of the six peptides is an FDA-approved drug.
- It is not a safety finding. HHS's own document says compounded drugs are not FDA-approved, which means the FDA does not review their safety, effectiveness, or quality before they are sold.
- It does not add them to the official list. Pharmacies normally may compound only with ingredients that meet official quality standards, are part of an FDA-approved drug, or appear on an official list created through FDA rulemaking. These six are not on that list, and the policy does not add them.
- It is not binding. HHS says the policy does not create rights for anyone and is not binding on HHS or the public.
For more background, see our guide to which peptides are FDA-approved.
What actually changed for patients?
The change is about how these peptides are made and tracked, not about whether they work. The policy applies to 503A pharmacies. A 503A pharmacy is a state-licensed pharmacy that makes medications for individual prescriptions. The policy also covers licensed physicians and federal facilities.
HHS lists ten conditions that must all be met. In plain terms, they come down to this:
- A real prescription for you. The product must be made for an individual patient with a valid prescription.
- Tested, traceable ingredients. The raw ingredient must come from an FDA-registered manufacturer. It needs a lab certificate showing it was tested for identity, purity, strength, and contaminants such as bacterial toxins and heavy metals.
- One peptide per product. No blends. HHS says this makes it easier to tell which substance caused a side effect.
- Side-effect reporting. Pharmacies must report serious side effects and quality problems to the FDA's MedWatch program and to the states involved. The label must say: "This is a compounded drug product. Not for resale."
- Only certain forms. Each peptide is limited to specific forms. For example, semax is limited to nasal use, and KPV to topical and oral forms. TB-500, epitalon, and MOTS-c are limited to injections. Pharmacies making oral products must keep records showing the product is adequately absorbed in humans. The only device that may be packaged with it is an FDA-cleared syringe.
If a product doesn't meet these conditions, the policy doesn't describe it. That includes peptides sold online as "research use only." Our explainer on 503A pharmacies versus foreign and research-only products explains the difference.
Why did HHS do this when FDA staff recommended against listing them?
Before a July 23-24, 2026 meeting, FDA staff reviewed all six peptides. In its briefing document, the FDA proposed that none of them be added to the official compounding list. The FDA also reviewed a seventh peptide, emideltide, which is not part of the HHS policy.
According to HHS's policy document, the FDA's Pharmacy Compounding Advisory Committee, which advises the FDA on compounding, voted in favor of including the six peptides. HHS's document also says the FDA's drug center recommended against listing each one.
HHS gives more than one reason. It says the policy will discourage the "widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients." In other words, HHS wants people to use tested products from licensed pharmacies instead of research-use-only products from foreign manufacturers. HHS also cites patient access while the FDA keeps reviewing these substances.
For each peptide, HHS points to newer lab-testing data and records of how the peptides have been used. Those are HHS's stated reasons. They are not new clinical trials.
What does the research say?
The policy is not evidence that any of these peptides helps any condition. BPC-157 shows how thin the human research is.
- A 2025 review in HSS Journal looked at 36 studies of BPC-157. Thirty-five were animal or lab studies. Only one was in people. The authors found no human safety data and warned about risks from unregulated manufacturing and contamination.
- A 2026 review in Acta Orthopaedica Belgica found only three human studies, with 30 people in total. Most participants reported feeling better without treatment-related side effects. But all three studies were judged poor quality, and the overall certainty of the evidence was rated very low. The authors said BPC-157 should not be used outside high-quality, regulated clinical trials.
None of the six peptides is FDA-approved. You can read more in our overviews of BPC-157's legal status, TB-500, and epithalon.
Is this permanent?
No. HHS calls it an interim policy, and the Federal Register notice also calls it a draft. It is not a final rule, and it is not binding.
- The public can comment for two weeks after the October 30 publication, through November 13, 2026.
- HHS says it may change the policy, in whole or in part, if a safety or product quality problem comes up.
- HHS says the policy lasts until each peptide is addressed in a final FDA rule, either adding it to the official compounding list or not.
The notice says future FDA rules "may propose adding some or all of these peptides" to the list. That is a possibility, not a promise.
What should you ask before trying any peptide?
Whether you're considering one of these six or any other peptide, these questions help separate a careful program from a risky one.
- Is it made by a state-licensed pharmacy, with a prescription written for me?
- Can the pharmacy show a lab certificate from an FDA-registered manufacturer?
- Is it a single-peptide product, in a form the HHS policy lists for that peptide?
- How do I report a side effect, and who do I call if I have one?
- What does the human research actually show for my goal, and what is still unknown?
Whether any of these peptides is appropriate for a given person is a medical decision, and for most uses the human evidence is not yet adequate to support one.
At Regen Therapy MD, any program starts with a physician consultation and baseline labs, with physician supervision throughout. Learn how our physician-supervised peptide therapy program is structured, review consult and program pricing, or read how to spot a real peptide program.
Frequently asked questions
Did HHS approve peptides?
No. In October 2026, HHS said it does not plan to take action against licensed pharmacies that make six peptides for individual prescriptions under strict rules. That is not approval. None of the six is FDA-approved, the FDA does not review compounded drugs for safety or effectiveness before they are sold, and human research on these peptides is very limited. The policy is also temporary and not binding.
Is BPC-157 legal now?
The policy does not make BPC-157 an approved drug, and it does not add it to the official compounding list. As of November 6, 2026, HHS says it does not plan to take action against licensed pharmacies and physicians that compound BPC-157 for an individual prescription under strict conditions. The policy is interim, not binding, and can change. A 2026 review rated the human evidence as very low certainty.
Which peptides are included in the HHS policy?
Six: BPC-157, TB-500, epitalon, semax, KPV, and MOTS-c. Each is limited to certain forms, such as nasal use for semax. The policy does not cover any other peptide. Being on this list is not approval. None of the six is FDA-approved, and the FDA had proposed against adding any of them to its official compounding list.
Are compounded peptides safe now?
The policy does not say they are. HHS's own document notes that compounded drugs are not FDA-approved and the FDA does not review their safety, effectiveness, or quality before they are sold. The conditions aim to improve testing and tracking. They do not prove safety. For BPC-157, for example, the few human studies are small and low quality, and none of the six is FDA-approved.
Does the policy cover "research use only" peptides sold online?
No. The policy does not cover "research use only" peptides sold online. HHS says it wants to discourage the widespread use of certain research-use-only peptides from foreign manufacturers, which it describes as a safety risk to U.S. patients. The policy only describes products made by licensed pharmacies or physicians, with tested ingredients and a prescription for an individual patient. None of the six peptides is an FDA-approved drug.
Talk with a Regen Therapy MD physician
If you'd like to talk through whether any of these options fit your health history, start with a physician consult, not a product.
- Book a consult: https://book.mypatientnow.com/practice/TqZLiT
- Call: (424) 349-6008
- Cost: $295 consult, credited 100% toward your first program
- Clinics: Beverly Hills (8920 Wilshire Blvd) and Santa Monica (2811 Wilshire Blvd). Telehealth and peptide shipping are available only where we are licensed.
Sources
- U.S. Department of Health and Human Services, Office of the Secretary. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Notice of availability; Docket No. HHS-OASH-2026-0496). Federal Register, 91 FR 68526, October 30, 2026. FR Doc. 2026-22192. https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
- U.S. Department of Health and Human Services. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, including Appendix A and Appendix B: Peptide Identities and Justifications for Placement of Peptide Bulk Drug Substances. October 2026. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
- U.S. FDA. FDA Briefing Document: Pharmacy Compounding Advisory Committee (PCAC) Meeting, July 23-24, 2026. https://www.fda.gov/media/193342/download
- U.S. FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee - 07/23/2026. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- Poolton JT, et al. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg. 2026. PMID 42885452. https://pubmed.ncbi.nlm.nih.gov/42885452/
- Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. PMID 40756949. https://pubmed.ncbi.nlm.nih.gov/40756949/
Educational disclaimer
This article is for educational purposes only and is not medical advice, diagnosis, or treatment. It doesn't establish a doctor-patient relationship or confirm that you are a candidate for any therapy. Individual results vary, and no outcome is promised. Study figures are group results from the cited publications, not predictions for any individual. Compounded drugs are not FDA-approved, and FDA-approved brand products and compounded preparations are not interchangeable. Retatrutide is investigational. This article doesn't provide dosing or treatment protocols. Talk with a licensed clinician about your own situation. If you have a medical emergency, call 911.
